Mouse EPHB4 / HTK Protein (His Tag)

Mouse Ephrin Type-B Receptor 4 / Developmental Kinase 2 Protein

EPHB4 / HTK Protein Product Information

• Synonym: AI042935, Htk, MDK2, Myk1, Tyro11
• Protein Construction: A DNA sequence encoding the mouse EPHB4 ( P54761-1 ) extracellular domain ( Met 1 - Ala 539 ) was fused with a polyhistidine tag at the C-terminus.
• Source: Mouse
• Expression Host: Human Cells

EPHB4 / HTK Protein QC Testing

• Purity: > 98 % as determined by SDS-PAGE
• Bio-activity: Measured by its binding ability in a functional ELISA
  Immobilized mouse EphB4 at 2 μg/ml ( 100 μl/well ) can bind mouse EphrinB2 with a linear range of 0.2 - 25 ng/ml
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Leu 16
• Molecular Mass: The secreted recombinant mouse EPHB4 comprises 535 amino acids and has a predicted molecular mass of 59 kDa. As a result of glycosylation, the apparent molecular mass of rm EPHB4/Fc monomer is approximately 70 kDa in SDS-PAGE under reducing conditions
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: EPHB4 protein

EPHB4 / HTK Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

EPHB4 / HTK Protein Description

Mouse EphB4, also known as Ephrin type-B receptor 4, Developmental kinase 2, Tyrosine kinase MYK-1, Htk and Myk-1, is a member of the Eph family of receptor tyrosine kinases (RTK). The Ephs are divided into two classes based on their extracellular structure and ligand specificity, and the transmembrane receptor binding preferentially to ephrin-B ligands is referred to as EphB. Sharing common structure organization, all Eph receptors contain an N-terminal Ig-like domain, a cysteine-rich region and two fibronectin type I II domains within the ECD, as well as the typical cytoplasmic tyrosine kinase domain. EphB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EphB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis, and tumor growth. In contrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EphB4 is associated with prostate cancer and highly malignant breast cancers, and accordingly, EphB4 has potential applications as a therapeutic candidate.

References

1. Huang X, et al. 2007, Cancer Res. 67 (20): 9800-8.
2. Noren NK, et al. 2007, Cancer Res. 67 (9): 3994-7.
3. Pennisi A, et al. 2009, Blood. 114 (9): 1803-12.
4. Noren NK, et al. 2009, Biochem J. 422 (3): 433-42.
5. Kumar SR, et al. 2009, Cancer Res. 69 (9): 3736-45.
6. Xu Z, et al., 2009, Expert Opin Ther Pat. 19 (7): 1035-7.